Greenwich LifeSciences, Inc. (NASDAQ: GLSI) provided an update on its Phase 3 FLAMINGO-01 clinical trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence, announcing that the study’s Data Safety Monitoring Board (DSMB) recommended the trial continue without modification following its May 2026 review. The company also said regulatory authorities in the U.S. and Europe have supported planned protocol changes that include expanding enrollment to as many as 2,000 patients, increasing enrollment rates by including all HLA types and maintaining enrollment through interim analyses to strengthen the study design and increase the probability of success.
The trial has already screened more than 1,500 patients across approximately 170 to 180 clinical sites in 11 countries, with plans to expand into additional European markets as well as the U.K. and Canada. This broader geographic reach could accelerate patient recruitment and data collection, potentially bringing the therapy closer to market. For leaders in business and technology, the expansion signals a substantial commitment to a large-scale, global clinical program that may influence future investment in cancer immunotherapy.
Greenwich LifeSciences also reported preliminary data from the fully enrolled open-label non-HLA-A*02 arm, which continues to show a 70% to 80% reduction in breast cancer recurrence following the primary immunization series. However, the company emphasized that these findings remain preliminary and are not predictive of the final Phase 3 results. The potential impact of a successful immunotherapy could be transformative for breast cancer patients, as recurrence prevention remains a significant unmet need. If confirmed, such efficacy could set a new standard of care and reshape the competitive landscape for oncology treatments.
For the pharmaceutical industry, the expanded study design—including all HLA types and continued enrollment during interim analyses—reflects a strategic approach to maximize the trial's statistical power and regulatory acceptance. This may serve as a model for other biotech companies designing pivotal studies. Investors and technology leaders should monitor the trial's progress, as positive outcomes could validate novel immunotherapy mechanisms and drive further innovation in precision medicine.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein expressed in a variety of common cancers, including 75% of breast cancers at low, intermediate, and high levels. For more information, visit the company’s website at www.greenwichlifesciences.com.
The full press release is available at https://ibn.fm/elLnNAbout.
